MDVN 112.77 Medivation Inc $MDVN Hit a 52 week high of 113.61 Closing the day 11/07/14 at 112.77 +7.82 +7.45% With a day low of 102.04 and a total volume of 3,348,268.
MDVN Recent Posts: http://investorshangout.com/Medivation-MDVN-54728/
MDVN Medivation Inc Recent Headline News
Look for Shares of Medivation to Potentially Pullback after Yesterday's 7.45% Rise
Comtex SmarTrend(R) - Fri Nov 07, 3:46PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $102.04 to a high of $113.61. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $106.79 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 112.77 (+7.82)
Clarification: Earns-Medivation story
AP - Fri Nov 07, 11:53AM CST
SAN FRANCISCO (AP) — In a story Nov. 7, The Associated Press reported that Medivation Inc. missed third-quarter earnings and revenue expectations based on the average of seven forecasts from Zacks Investment Research. The story was later updated to reflect that the company beat expectations based on the average of 18 estimates from FactSet.
MDVN: 112.77 (+7.82)
Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72)
Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 112.77 (+7.82), AOL: 42.68 (+0.45), AZN: 72.88 (+0.03)
Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Marketwired - Thu Nov 06, 3:13PM CST
Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million.
MDVN: 112.77 (+7.82)
Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Nov 05, 3:11PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 112.77 (+7.82)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
at The Street - Wed Nov 05, 7:00AM CST
The diversification away from Xtandi has only just begun.
MDVN: 112.77 (+7.82)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), PRGO: 155.77 (+3.28), ALNY: 95.84 (+2.93)
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ALNY: 95.84 (+2.93), HUM: 130.58 (-9.29)
Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), GERN: 2.33 (-0.07)
Geron Corporation (GERN) Looks Strong: Stock Up 25.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:44AM CST
Geron Corporation (GERN) was a big mover last session, as the company saw its shares surge nearly 26% on the day
MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), GERN: 2.33 (-0.07), ILMN: 186.35 (-3.52)
Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), ALNY: 95.84 (+2.93), HSP: 56.32 (-0.32)
Will DaVita Healthcare (DVA) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:40PM CST
DaVita Healthcare Partners, Inc. (DVA) is set to report third-quarter 2014 earnings on Nov 6, 2014.
MDVN: 112.77 (+7.82), AMSG: 51.50 (+0.16), DVA: 74.49 (-3.54), ALNY: 95.84 (+2.93)
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)
Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:39AM CST
Prosensa Holding N.V. (RNA) was a big mover last session, as its shares rose nearly 10% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), RNA: 12.14 (+0.08), ILMN: 186.35 (-3.52)
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:51AM CST
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as its shares rose nearly 7% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), ALDR: 16.57 (-0.25), ILMN: 186.35 (-3.52)
Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:44AM CST
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares surge nearly 22% on the day
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), ILMN: 186.35 (-3.52)
MDVN Recent Posts: http://investorshangout.com/Medivation-MDVN-54728/
MDVN Medivation Inc Recent Headline News
Look for Shares of Medivation to Potentially Pullback after Yesterday's 7.45% Rise
Comtex SmarTrend(R) - Fri Nov 07, 3:46PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $102.04 to a high of $113.61. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $106.79 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 112.77 (+7.82)
Clarification: Earns-Medivation story
AP - Fri Nov 07, 11:53AM CST
SAN FRANCISCO (AP) — In a story Nov. 7, The Associated Press reported that Medivation Inc. missed third-quarter earnings and revenue expectations based on the average of seven forecasts from Zacks Investment Research. The story was later updated to reflect that the company beat expectations based on the average of 18 estimates from FactSet.
MDVN: 112.77 (+7.82)
Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72)
Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 112.77 (+7.82), AOL: 42.68 (+0.45), AZN: 72.88 (+0.03)
Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Marketwired - Thu Nov 06, 3:13PM CST
Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million.
MDVN: 112.77 (+7.82)
Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Nov 05, 3:11PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 112.77 (+7.82)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
at The Street - Wed Nov 05, 7:00AM CST
The diversification away from Xtandi has only just begun.
MDVN: 112.77 (+7.82)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), PRGO: 155.77 (+3.28), ALNY: 95.84 (+2.93)
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ALNY: 95.84 (+2.93), HUM: 130.58 (-9.29)
Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), GERN: 2.33 (-0.07)
Geron Corporation (GERN) Looks Strong: Stock Up 25.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:44AM CST
Geron Corporation (GERN) was a big mover last session, as the company saw its shares surge nearly 26% on the day
MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), GERN: 2.33 (-0.07), ILMN: 186.35 (-3.52)
Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), ALNY: 95.84 (+2.93), HSP: 56.32 (-0.32)
Will DaVita Healthcare (DVA) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:40PM CST
DaVita Healthcare Partners, Inc. (DVA) is set to report third-quarter 2014 earnings on Nov 6, 2014.
MDVN: 112.77 (+7.82), AMSG: 51.50 (+0.16), DVA: 74.49 (-3.54), ALNY: 95.84 (+2.93)
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)
Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:39AM CST
Prosensa Holding N.V. (RNA) was a big mover last session, as its shares rose nearly 10% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), RNA: 12.14 (+0.08), ILMN: 186.35 (-3.52)
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:51AM CST
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as its shares rose nearly 7% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), ALDR: 16.57 (-0.25), ILMN: 186.35 (-3.52)
Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:44AM CST
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares surge nearly 22% on the day
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), ILMN: 186.35 (-3.52)
